139 related articles for article (PubMed ID: 23226795)
1. RagD gene expression and NRF2 mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Lett; 2012 Dec; 4(6):1167-1170. PubMed ID: 23226795
[TBL] [Abstract][Full Text] [Related]
2. MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Oct; 6(4):705-8. PubMed ID: 22767273
[TBL] [Abstract][Full Text] [Related]
3. Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Aug; 6(2):391-4. PubMed ID: 22614957
[TBL] [Abstract][Full Text] [Related]
4. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
5. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
[TBL] [Abstract][Full Text] [Related]
6. RagD regulates amino acid mediated-casein synthesis and cell proliferation via mTOR signalling in cow mammary epithelial cells.
Mu Y; Zheng D; Wang C; Yu W; Zhang X
J Dairy Res; 2018 May; 85(2):204-211. PubMed ID: 29785899
[TBL] [Abstract][Full Text] [Related]
7. Genotype analysis of the NRF2 gene mutation in lung cancer.
Sasaki H; Suzuki A; Shitara M; Hikosaka Y; Okuda K; Moriyama S; Yano M; Fujii Y
Int J Mol Med; 2013 May; 31(5):1135-8. PubMed ID: 23545629
[TBL] [Abstract][Full Text] [Related]
8. A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue.
Bowman BM; Montgomery SA; Schrank TP; Simon JM; Ptacek TS; Tamir TY; Mulvaney KM; Weir SJ; Nguyen TT; Murphy RM; Makowski L; Hayes DN; Chen XL; Randell SH; Weissman BE; Major MB
J Pathol; 2020 Oct; 252(2):125-137. PubMed ID: 32619021
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
10. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
Kim YR; Oh JE; Kim MS; Kang MR; Park SW; Han JY; Eom HS; Yoo NJ; Lee SH
J Pathol; 2010 Mar; 220(4):446-51. PubMed ID: 19967722
[TBL] [Abstract][Full Text] [Related]
12. [Role and mechanism of SIRT1 in regulating Nrf2/HO-1 signaling pathway in septic liver injury].
Chen M; Zhang Y; Wang Y; Gulifeire T; Yu X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Jun; 35(6):598-603. PubMed ID: 37366125
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
14. [Effect of SIRT1 regulating Nrf2/HO-1 signaling pathway on sepsis-induced acute lung injury].
Zhang Y; Chen M; Wang Y; Li X; Yu X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Mar; 35(3):244-249. PubMed ID: 36916335
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
16. NRF2-Driven
Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L
Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
18.
Sasaki H; Suzuki A; Tatematsu T; Shitara M; Hikosaka Y; Okuda K; Moriyama S; Yano M; Fujii Y
Biomed Rep; 2014 May; 2(3):392-395. PubMed ID: 24748981
[TBL] [Abstract][Full Text] [Related]
19. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
20. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
